Infectious Disease · Medical Literature
[Newsdesk] Trials of medical countermeasures to begin in DR Congo
Abstract
Three drugs for Bundibugyo virus treatment and prevention are set to be tested in DR Congo under a previously established protocol for an adaptive platform trial. Esther Nakkazi reports.
Clinical relevance
Can the investigational agents MBP134 (pan-ebolavirus monoclonal antibody cocktail), remdesivir (intravenous antiviral), and obeldesivir (oral antiviral for post-exposure prophylaxis) improve survival or prevent Bundibugyo virus disease (BVD) in confirmed cases and high-risk contacts during the active 2026 outbreak in the Democratic Republic of the Congo and Uganda? __SNAPSHOT__ {"studyDesign":"Two linked adaptive platform trials currently in enrollment phase: (1) PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) — a randomized adaptive platform trial evaluating treatment in confirmed BVD cases; (2) EBO-PEP BUNDI — a randomized adaptive platform trial evaluating post-exposure prophylaxis in high-risk contacts. This Lancet Infectious Diseases article is a newsdesk report describing trial initiation, not a completed study or results paper.","setting":"Active outbreak setting; Ituri province, Democratic Republic of the Congo (primary epicenter), with planned expansion to Uganda and potentially other Sub-Saharan African countries (DRC, Uganda, Guinea, Liberia, Sierra Leone for EBO-PEP). PARTNERS coordinated by WHO, INRB (Kinshasa), Institute of Tropical Medicine (Belgium), and University of Oxford (UK), with field delivery by ALIMA and MSF.","sampleSize":"Target enrollment of at least 1,000 participants across trials; actual enrollment ongoing as of July 2026. Final numbers dependent on outbreak trajectory. Not yet reported.","population":"PARTNERS: Patients with confirmed Bundibugyo virus disease. EBO-PEP BUNDI: High-risk contacts of confirmed filovirus disease cases. As of June 25, 2026, there were 1,138 confirmed cases in DRC (CFR 26%) and 20 confirmed cases in Uganda; by July 9, 2026, cumulative deaths reached approximately 600 with 1,759 total infections.","intervention":"PARTNERS: MBP134 (pan-ebolavirus bispecific monoclonal antibody cocktail comprising ADI-15878AF and ADI-23774AF, targeting non-overlapping glycoprotein epitopes) given alone, remdesivir (intravenous broad-spectrum antiviral) given alone, and MBP134 plus remdesivir in combination. EBO-PEP BUNDI: Obeldesivir (oral antiviral prodrug of remdesivir, developed by Gilead Sciences), administered twice daily to high-risk contacts.","comparator":"Adaptive platform design with randomized allocation; specific comparator arms (e.g., standard supportive care alone) not fully specified in available abstract and newsdesk report. Not reported in detail.","primaryOutcome":"PARTNERS: Survival improvement among patients diagnosed with BVD (specific primary endpoint definition, time point, and statistical threshold not reported in available sources). EBO-PEP BUNDI: Efficacy of obeldesivir as post-exposure prophylaxis in preventing onset of BVD among high-risk contacts (specific primary endpoint not reported in available sources). Follow-up after enrollment is at least 28 days per WHO protocol.","followUp":"Minimum 28 days post-enrollment per WHO protocol; full trial duration estimated at several months to approximately one year depending on enrollment rate and outbreak course.","fundingSource":"Multi-source: WHO (PARTNERS trial sponsor); Global Health EDCTP3 partnership supported by the European Commission (EUR 3.4 million to EBO-PEP); Africa CDC (USD 1 million direct financing for EBO-PEP); South Africa (USD 2 million); DRC government (USD 3 million); Africa CDC also calling for USD 18 million for the full research program. ANRS Emerging Infectious Diseases/Inserm (EBO-PEP co-conductor). Industry involvement (Gilead Sciences as developer of obeldesivir) not fully characterized in available sources."}
Key findings
This Lancet Infectious Diseases newsdesk report describes trial initiation only; no efficacy, safety, or outcome data are available. No primary results, effect sizes, confidence intervals, p-values, or adverse event data have been reported. The PARTNERS trial opened enrollment on July 2, 2026, and the EBO-PEP BUNDI trial opened enrollment on July 14, 2026, both in Ituri province, DRC. Preclinical rationale for MBP134 includes non-human primate data demonstrating protection against lethal Bundibugyo virus challenge with a single dose, with protection observed even when treatment was initiated on day 7 post-infection in viremic, symptomatic animals. Obeldesivir has shown preclinical efficacy against multiple filoviruses including Bundibugyo virus. No human efficacy data for any of the three agents against Bundibugyo virus disease have been reported to date. The contextual epidemiological burden as of July 9, 2026 includes approximately 1,759 infections and 600 deaths in DRC and Uganda combined (CFR approximately 34% at that timepoint, calculated), with Ituri province accounting for approximately 91% of confirmed DRC cases.
Practice implications
This article establishes that, for the first time in history, randomized clinical trials are actively enrolling patients with confirmed Bundibugyo virus disease and high-risk contacts in an active outbreak setting. It does NOT establish efficacy or safety of any intervention. Prior to these trials, no licensed vaccine or approved therapeutic existed specifically for BVD, and no treatment had been demonstrated effective across all Ebola species — approved agents (Ebanga, Inmazeb) are licensed only for Zaire ebolavirus. The rationale for MBP134, remdesivir, and obeldesivir is grounded in preclinical data and mechanistic cross-species immunological reasoning, not human BVD-specific clinical trials. The adaptive platform design allows for addition or removal of treatment arms based on accumulating evidence and DSMB review, which is methodologically appropriate for an outbreak context. Patients not yet represented include pregnant women, children, immunocompromised individuals, and patients outside Ituri province; generalizability to future non-outbreak settings is unknown. Results are not expected for at minimum several months. Clinicians should be aware that current standard of care for BVD remains supportive only; these trials represent the mechanism to change that, not the evidence to change practice yet. Only the abstract and supplementary journalistic/institutional sources were available; the full trial protocol was not reviewed. __LIMITATIONS__ 1. No results: This is a trial-launch news report, not a completed study; no efficacy, safety, or outcome data exist yet. 2. Outbreak-dependent enrollment: Final sample size is contingent on outbreak trajectory; underpowering is a meaningful risk if the outbreak is controlled before target enrollment is reached. 3. Single-site initial enrollment: Enrollment began at one site in Ituri province, raising concerns about geographic and demographic representativeness. 4. Preclinical-to-clinical translation gap: Justification for all three agents rests substantially on non-human primate data and extrapolation from Zaire ebolavirus studies; cross-species efficacy is not guaranteed. 5. No approved comparator: The absence of a licensed BVD therapeutic means the comparator is supportive care, which while ethically appropriate, does not permit benchmarking against a known effective agent. 6. Operational constraints: Active outbreak conditions in a resource-limited, conflict-affected region introduce risks of protocol deviations, incomplete follow-up, and data quality challenges. 7. Adaptive design complexity: While methodologically advantageous, adaptive platform trials require robust real-time statistical oversight and pre-specified adaptation rules, details of which are not available in the abstract. 8. Potential industry influence: Gilead Sciences developed obeldesivir; the degree of industry involvement in trial design or data access is not reported. 9. Diagnostic gap: GeneXpert, the most common frontline diagnostic in this outbreak, does not detect Bundibugyo virus, potentially delaying case confirmation and complicating enrollment. 10. Abstract/newsdesk only: Full protocol, statistical analysis plan, pre-specified endpoints, and randomization details were not available for review. __BOTTOM_LINE_CATEGORY__ not_ready_for_clinical_application __BOTTOM_LINE__ The PARTNERS and EBO-PEP BUNDI adaptive platform trials represent the first-ever randomized evaluation of therapeutics (MBP134, remdesivir) and post-exposure prophylaxis (obeldesivir) for Bundibugyo virus disease, an Ebola species for which no licensed treatment or vaccine currently exists. No efficacy or safety data are yet available; current standard of care remains supportive only. Clinicians should monitor these trials for results anticipated within months to approximately one year, as positive findings would be immediately practice-changing in the setting of BVD outbreaks.